These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8103375)

  • 1. Pharmaco-economic considerations in the long-term management of peptic ulcer disease.
    Ruszniewski P
    Aliment Pharmacol Ther; 1993; 7 Suppl 2():41-8. PubMed ID: 8103375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and health aspects of peptic ulcer disease and H2-receptor antagonists.
    Jensen DM
    Am J Med; 1986 Oct; 81(4B):42-8. PubMed ID: 2877574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Economic analysis of maintenance treatment with ranitidine 150 mg in duodenal ulcer].
    Ruszniewski P; Levy E; Mignon M
    Gastroenterol Clin Biol; 1992; 16(11):842-7. PubMed ID: 1483552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic assessment of peptic ulcer disease treatments.
    Jensen DM
    Scand J Gastroenterol Suppl; 1988; 146():214-24. PubMed ID: 2906466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cimetidine and the cost of peptic ulcer in the Netherlands.
    Bulthuis R
    Eff Health Care; 1984 Apr; 1(6):297-311. PubMed ID: 10310799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.
    Freston JW
    Am J Gastroenterol; 1987 Dec; 82(12):1242-9. PubMed ID: 2891294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histamine H2-receptor antagonists as new anti-ulcer agents].
    Takemoto T
    Nihon Rinsho; 1984 Jan; 42(1):103-13. PubMed ID: 6143835
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
    Bardhan KD; Naesdal J; Bianchi Porro G; Petrillo M; Lazzaroni M; Hinchliffe RF; Thompson M; Morris P; Daly MJ; Carroll NJ
    Gut; 1991 Apr; 32(4):435-8. PubMed ID: 1673953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization.
    Brufsky JW; Ross-Degnan D; Calabrese D; Gao X; Soumerai SB
    Med Care; 1998 Mar; 36(3):321-32. PubMed ID: 9520957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
    Belousov IuB; Karpov OI; Belousov DIu; Beketov AS
    Ter Arkh; 2007; 79(2):58-66. PubMed ID: 17460971
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapy and prevention of duodenal and gastric ulcer with histamine-H2-receptor antagonists].
    Hentschel E
    Wien Med Wochenschr; 1983; 133(4-5):104-7. PubMed ID: 6134397
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of cimetidine on the cost of ulcer disease in Sweden.
    Jönsson B; Carlsson P
    Soc Sci Med; 1991; 33(3):275-82. PubMed ID: 1925691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].
    Simon B; Müller P; Dammann HG
    Wien Med Wochenschr; 1982 May; 132(10):223-8. PubMed ID: 6126962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranitidine v. cimetidine in peptic ulcer.
    Drug Ther Bull; 1982 Jul; 20(15):57-9. PubMed ID: 6128213
    [No Abstract]   [Full Text] [Related]  

  • 15. H2-blockers: how safe and how effective?
    Spiro HM
    J Clin Gastroenterol; 1983; 5 Suppl 1():143-7. PubMed ID: 6140282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptic ulcer in cirrhotic patients: a short- and long-term study with antisecretory drugs.
    Di Mario F; Gottardello L; Germanà B; Dotto P; Grassi SA; Vianello F; Battaglia G; Leandro G; Burra P; Salvagnini M
    Ital J Gastroenterol; 1992; 24(3):122-5. PubMed ID: 1348650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
    Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
    Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
    [No Abstract]   [Full Text] [Related]  

  • 18. [A comparative evaluation of the efficacy of sucralfate and H2-histamine blockaders in treating peptic ulcer].
    Ivashkin VT; Tkachenko EI; Grinevich VB; Sultanov VK; Inozemtsev SA
    Ter Arkh; 1989; 61(8):59-62. PubMed ID: 2573963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy of duodenal ulcer with H2-receptor antagonists--a meta-analysis.
    Palmer RH; Frank WO; Karlstadt R
    Aliment Pharmacol Ther; 1990 Jun; 4(3):283-94. PubMed ID: 1983324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulary management of antiulcer drugs: economic considerations.
    Tucker PP; Nash DB
    Pharmacoeconomics; 1994 Apr; 5(4):313-34. PubMed ID: 10147240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.